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Background: Public health nurses report on effects of fresh human milk as treatment for conjunctivitis, rhinitis and
atopic eczema (AE), the latter being highly prevalent in early childhood. Emollients and topical corticosteroids are
first line treatment of AE. As many caregivers have steroid phobia, alternative treatment options for mild AE are of
interest. The aim of this small pilot study was to assess the potential effects and risks of applying fresh human milk
locally on eczema spots in children with AE.
Methods: This was a split body, controlled, randomized and physician blinded pilot study, of children with AE with
two similar contralateral eczema spots having a mother breastfeeding the child or a sibling. Fresh expressed milk
and emollient was applied on the intervention spot and emollient alone on the control area, three times a day for
four weeks. The severity and area of the eczema spots was evaluated weekly, and samples from milk and the spots
were analysed weekly with respect to bacterial colonisation.
Results: Of nine patients included, six completed the study. Mean age at inclusion was 18.5 months. The spots
examined were localized on the arms, legs or cheeks. The spots were similar in severity, but differed in area. In one
patient the eczema ceased after inclusion. In four patients both control and intervention areas increased during the
intervention. The relative change in eczema area compared to baseline showed less increase in the intervention
spots in two patients, whereas the opposite was observed in three. In four children Staphylococcus aureus was
found in their eczema once or more. In three of the 28 human milk samples, Staphylococcus aureus, alfa haemolytic
streptococci or coagulase negative staphylococci were detected. Staphylococcus aureus was found once both in
human milk and in the eczema spots, no clinical signs of infection were however observed. No secondary infection
due to milk application was detected.
Conclusion: In this small pilot study, no effect was found on eczema spots treated with topical application of fresh
human milk. (ClinicalTrials.gov Identifier, NCT02381028).
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Atopic eczema (AE) is a common, chronic, pruritic,
relapsing skin disease which affects up to 20% of children
in the Nordic European countries [1]. AE is strongly
associated with other atopic disorders, such as allergic
rhinitis and asthma [2]. The pathogenesis is interplay
between barrier dysfunction, genetic, immunological,
environmental factors and colonization by Staphylococcus
aureus (S. aureus) [3].
The treatment algorithm in AE is based on treating
the barrier defect, the inflammation, the infection and
the pruritus [4]. First line treatment is treating the
barrier defect with optimal skin care by the use of
emollients and baths. If a clinical infection is present
in the eczema, local antiseptics may be utilized; for severe
cases systemic antibiotics are needed. The inflammation is
treated with topical steroid creams. Topical steroids have
been shown to be a well-tolerated treatment, but in spite
of this many caregivers have steroid phobia, mainly
because of the potential side effects [5]. A treatment
option in chronic eczema is topical calcineurin inhibitors;
these are however not to be used in children under two
years of age [4]. Alternatives without side effects for young
children are therefore of interest.
Human milk may represent a source with potential
treatment properties. Knowledge of the immunological
qualities of mammalian milk can be traced back to 1892,
when Paul Ehrlich demonstrated that newborn mice were
protected against the toxic effects of phytotoxins if they
were fed milk from an immunized mouse [6]. Today,
numerous studies have contributed to our present
knowledge of the short- and long-term effects of human
milk in the breastfed child [7]. Mammalian milk is species
specific. Human milk contains specialized immune
components, including factors with anti-microbial and
anti-inflammatory properties [8], which theoretically
could be responsible for an effect on eczema spots
when applied topically.
In Norway, public health nurses report several cases
where parents have had positive experiences with topic
applications of expressed human milk in eyes of children
with conjunctivitis and on eczema spots in children with
AE. We have not been able to find any studies investigating
such treatment in children with AE. However, local
use of expressed human milk has been studied for
diaper dermatitis, rhinitis and conjunctivitis [9,10].
The aim of this small pilot study was to assess the
potential positive and/or negative effects of topical
use of expressed, fresh human milk on eczema spots
in young children with AE by evaluating the eczema
areas. A secondary aim was to evaluate any bacterial
transmission from human milk to the eczema spots,
causing infection in the child. Finally the mothers’
compliance to the treatment was of interest.Methods
Trial design
This was a split body controlled, randomized and physician
blinded study of expressed human milk and emollients on
contralateral eczema spots in children, the trial was regis-
tered at ClinicalTrials.gov Identifier, NCT02381028.
Inclusion criteria were children with AE according to
Hanifin and Rajkas criteria [11] with a mother breastfeeding
the child or a sibling. The eczema spots in the treatment
and control areas were to be similar in features and extent
as well as being localized on contralateral parts of the
body. Children were excluded if the severity of the eczema
spots indicated need for treatment with antibiotics and/or
steroids.
The study was approved by the Regional Committee for
Medical and Health Research Ethics - South East Norway.
Mothers of participating children were informed verbally
and in writing, and signed an informed consent prior to
commencing the study.
Recruitment
Study patients were recruited through advertisement
posters from three different well baby clinics in Oslo,
Norway, in the period 2008–2011. Mothers interested in
the study contacted the study team. The consultations
mainly took place at the hospital; a few were carried out
in the child’s home. The mothers were able to contact the
examining physician if they experienced any problems
with the treatment.
Intervention
The study intervention was local application of fresh
human milk on the study area. By hand milking, the
mothers were to squeeze out and throw away the first few
droplets of milk, and then squeeze the next droplets
directly from the nipple to the eczema spot. The number of
milk droplets depended on the size of the eczema area; the
mothers were instructed to cover the whole eczema spot
with milk. After absorption of the milk droplets, both treat-
ment and control areas were treated with moisturizing
cream (Apobase creme®, Actavis Norway AS). The cream
contains: Aqua, Paraffinum Liquidum, Petrolatum, Cetearyl
Alcohol, Ceteareth-20, Ceteareth-12, Sodium Gluconate,
Caprylyl Glycol, Phenoxyethanol, with a total lipid content
of 30 percent. Both intervention and control areas were
treated with this regimen three times a day for four weeks.
Randomization and blinding
The same physician examined all the children, and was
blinded as to which areas were the control or intervention
sites. At inclusion the physician diagnosed the AE according
to Hanifin and Rajkas criteria [11]. The two contra-lateral
eczema spots to be randomized were elected; i.e. flexural
aspect of elbow, flexural aspect of knees or cheeks. Another
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Figure 1 Flow diagram. Nine children with atopic eczema and bilateral eczema lesions were assessed for eligibility to a small split body,
controlled, physician blinded pilot study evaluating human milk and emollient versus emollient alone on eczema lesions. Three children
were lost to follow up.
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randomization. The child was given a randomization
number and the mothers were then informed on which side
to apply the fresh expressed human milk and emollient,
and on which side to apply emollient alone.
Follow-up
After inclusion, the children were examined once weekly
for four consecutive weeks. The overall severity of AE
was evaluated by the use of SCORAD, which defines
mild disease as score <25, moderate disease between
25–50 and severe disease as scores >50 [12]. The severity
of the study and control areas were evaluated by scoring
the erythema, lichenification, excoriation and pruritus on
a scale from 0 to 3, where 0 is none and 3 is severe. Study
and control areas were measured using Visitrak™ (Smith &
Nephew), a portable device used to measure the area of
wounds [13]. A transparent folio is placed over the area
and the borders are outlined, whereafter a computer
determines the area measured in cm2. In the present
study this device was used to follow the development
of the extent of the eczema spots.At each visit, samples for bacterial cultures were taken at
eczema spots and from breastmilk, using Amies Agar Gel
with CharcoalTM, Copan Venturi Transystem® (Copan,
Brescia, Italy). Sampling from eczema spots was done by
carefully rubbing the cotton swab over the eczema spot.
Sampling of breastmilk was done from milk expressed by
hand milking. The specimens were cultivated on blood
agar plates and selective media for S. aureus and for
gram-negative rods.
Outcome
The primary outcome was to register proportional change
in the area of the eczema spot from baseline, as measured
by Visitrak™. The secondary outcome was to assess trans-
mission of bacteria from mother’s milk to eczema spots in
the child. The mother’s compliance was also evaluated.
Statistical methods
Descriptive statistics were performed. The areas of the
intervention and control sites for each child were not
identical; therefore differences were calculated as
percentages: Changes in the areas of the control and
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proportion of area related to baseline area.
Results
Study population
Nine children, four male, were recruited for the study
through advertisement posters from three different well
baby clinics in Oslo, Norway in the period 2008–2011.
Three of these nine children were lost to follow-up
consultations; one experienced remission from AE, the
second suffered from severe AE and was hospitalized, the
third never met for follow up (Figure 1). Two children
were treated with mothers’ milk produced for a younger
sibling. The mean age of the children was 18.5 months
(min, max; 4, 32). At inclusion mean SCORAD was 35
(min, max; 22, 45) and at the end of the study mean
SCORAD was 34 (min, max; 18, 52). The spots examined
were localized on the arms or legs in five of the children
and on the cheeks in one. The spots were similar in severity,
however the extent differed some.
Changes in measured area of eczema
The weekly change in the control and intervention eczema
area related to baseline eczema area is illustrated in
Figure 2. At the end of the study, child number one
and seven displayed less area involvement in the area
treated with human milk compared to the emollientFigure 2 Change in eczema area. This figure illustrates the weekly differen
from baseline in six children with atopic eczema included in a split body, c
emollient versus emollient alone on eczema lesions. Each line represents o
divided by control area at week 0 minus intervention area week 1, 2, 3 or 4
improvement of the intervention area, and lines below zero represent thetreated area. In child number two, five and nine the
emollient treated area showed at study end less
involvement than the area treated with human milk.
The eczema spots in child number eight disappeared
after inclusion.
Most of the children showed an improvement of their
general eczema, except for child five, who showed a
slight increase. Child seven differs from the other children:
this child experienced a worsening of the total eczema,
having mild atopic eczema at inclusion, and severe atopic
eczema at week four.
Changes in presence of bacterial species
Four of the children had positive S. aureus cultures in
their eczema once or more (Table 1). However, only in
four of twelve occasions this coincided with clinical signs
of infection. Gram-negative rods were found in child
number one at one visit. S. aureus, alfa haemolytic
streptococci or coagulase-negative staphylococci were
detected in three of the 28 human milk samples. Only
on one occasion the same bacteria (S. aureus) were
detected in both the eczema lesions and the human
milk (child number five), and signs of clinical infection
were present (Table 1). The intervention areas differed
some from the control areas, as S. aureus was found in
intervention area but not in the control area on four
occasions in three different children (Table 1).ce between control and intervention sites based on the area change
ontrolled, physician blinded pilot study evaluating human milk and
ne child. The difference is calculated as: control area week 1, 2, 3 or 4
divided by intervention area at week 0. Lines above zero represent
relative increase of the eczema areas of the intervention sites.
Table 1 Bacteria in eczema spots and human milk
Child Week Clinical infected Study area Control area Human milk
1 0 No No growth No growth Skin flora1
1 No No growth No growth Missing
2 No No growth Skin flora Missing
3 No Gram negative rods Gram negative rods Skin flora
4 No Skin flora No growth Skin flora
2 0 No Skin flora Skin flora Skin flora
1 No Skin flora Skin flora Skin flora
2 No Skin flora Skin flora Skin flora
3 No Skin flora Skin flora Skin flora
4 No No growth No growth Skin flora
5 0 No S. aureus (rich) S. aureus (mod.2) Skin flora
1 No S. aureus (rich) S. aureus (rich) S. aureus (some col.3)
2 Yes S. aureus (mod.) S. aureus (sparse) Skin flora
3 No S. aureus (rich) S. aureus (rich) Skin flora
4 Yes S. aureus (mod.) Skin flora Skin flora
7 0 No Skin flora Skin flora Skin flora
1 Yes Skin flora Skin flora CNS4
2 No S. aureus (some col.) Skin flora Skin flora
3 No Skin flora Skin flora Skin flora
4 No S. aureus (some col.) Skin flora Skin flora
8 0 No Missing Missing Missing
1 No Skin flora Skin flora Skin flora
2 No Skin flora Skin flora Skin flora
3 No S. aureus (some col.) Skin flora Skin flora
4 No Skin flora Skin flora Skin flora
9 0 No S. aureus (some col.) S. aureus (sparse) Skin flora
1 Yes S. aureus (mod.) S. aureus (rich) AHST5
2 No S. aureus (sparse) S. aureus (mod.) No growth
3 Yes S. aureus (mod.) S. aureus (some col.) Skin flora
1Skin flora: non-pathogen bacteria belonging to the skin flora 2 mod.: moderate, 3col. colonies, 4CNS: coagulase negative staphylococci, 5AHST alfa
haemolytic streptococci.
Bacterial presence in samples taken from eczema spots and human milk weekly, and the presence of clinically judged infection in control and intervention sites of
six children with atopic eczema included in a split body, controlled, physician blinded pilot study evaluating human milk and emollient versus emollient alone on
eczema lesions.
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The mothers experienced the application of human milk
as an uncomplicated treatment option.
Discussion
In this small, split body controlled randomized pilot
study of human milk and emollient applied topically on
eczema spots in six children, no effect was found on
eczema spots treated with the topical application of fresh
human milk. In two of five children with persistent
eczema lesions during the study, there was less
involvement of the human milk treated area compared tothe emollient area at study end compared to baseline.
However, the opposite was found in three children.
There are few studies looking at the effect of human
milk on eczema. One study of children with diaper
dermatitis examined the effect of applying human milk
after each breastfeeding or hydrocortisone 1% ointment
twice a day, detecting after one week an effect of human
milk comparable to that of hydrocortisone [9]. The
application frequency was higher than in our study,
but we still believe that an application rate of three times
a day would be enough to show an effect of human milk,
after four weeks of treatment.
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milk can be effective on eczema lesions. One aspect of
atopic disease is the type 2 helper T cell (Th2) dysbalance
with production of interleukin- 4 (IL-4), IL-5, and IL-13 in
the acute phase. In the chronic phase there is a Th1/Th0
dominance with production of interferon-γ, IL-2, IL-5 and
granulocyte-macrophage colony-stimulating factor [2]. Of
interest, therefore, are findings from an animal model,
where the effect of human colostrum used locally on an
acute inflammatory process was shown to be as potent as
oral indomethacin and superior to oral dexamethasone at
suppressing polymorphonuclear leukocyte influx [14,15].
In humans, the milk contains, among a wide variety of
biologically active hormones, glucocorticoids. These are
transferred from plasma to the milk in levels fairly highly
correlated (in the .6-.7 range) [16].
Milk samples from healthy donors have revealed
bacteria in 10–23% of the samples [17]. In the present
study, bacteria were found in three of 28 samples; 11%.
In one child only (child number five), S. aureus was
found once in both the eczema spot and in the milk.
Clinically, however, the eczema was not infected, and
this child had S. aureus on both eczema lesions at every
visit. This suggests that no iatrogenic infections due to
application of fresh mothers milk occurred. Surprisingly,
S. aureus was found in the intervention area but not in
the control area on four occasions in three different
children. One speculation might be that the preserva-
tive (eg. phenoxyethanol) in the emollient had some
antimicrobial effect when applied alone.
Human milk contains several different substances that
act against bacteria, virus and fungi, such as Secretory IgA
and Secretory IgM [18], lactoferrin, lysozyme, oligosaccha-
rides, Toll-like receptors and fatty acids [8]. In a study
evaluating the inhibition in vitro of human colostrum
against bacterial cultures from eye swabs of neonates with
neonatal conjunctivitis, the inhibitory activity was ≥ 50%
against S. aureus and coliform bacteria, demonstrating
an antimicrobial effect also in vitro [19]. A consistent
inhibitory effect of human milk was found against
Neisseria gonorrhea in children with conjunctivitis. A
significant but less pronounced effect was also found
against Moraxella catarrhalis [10]. This strengthens the
evidence for an antimicrobial effect of human milk also
when used topically. When comparing different methods
for preventing omphalitis in newborns, an application
frequency of topical human milk twice a day demonstrated
a shorter separation time of the umbilical stump compared
to the use of antiseptics [20]. In the study of Ibhanesebhor
[19], the mean duration of inhibition of human milk against
S. aureus was three hours. Considering the huge amount of
different biologically active components and cells in human
milk, there might be a variety of candidates for explaining
the positive effects described above.The children participating in the present study were
recruited through advertisement posters in well baby
clinics, and responding mothers were presumably highly
motivated and inclined to trust alternative/new treatment
methods. We cannot rule out that the mothers co-treated
the intervention sites with for instance steroid cream, but
the instructions with respect to treatment of the interven-
tion and control site were clear, and the results do not
indicate performance bias.
Conclusions
The results of this small randomized, controlled pilot
study of six children with AE does not support an effect
of topical applied human milk. Treatment with fresh
expressed human milk seems safe and easy for mothers
to carry out.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TLB, BFL, JR, ES and GN were all involved in the design of the study,
drafting the protocol, analysing results and writing the paper. TLB provided
methodological considerations and carried out the clinical part. PG was
involved in analysing the bacteria cultures and in writing the paper.
All authors read and approved the final manuscript.
Acknowledgements
We thank the children and their parents for cooperation in this study.
The study team gratefully acknowledge Dr. PhD. Kristin Bergersen, Institute
of Clinical Medicine, University of Oslo and Department of Dermatology,
Oslo University Hospital, Oslo, Norway, for her important contribution to
the initial study design. The team also acknowledge preliminary analyses
provided by Mari Vårdal, Department of Biostatistics, Epidemiology and
Health Economy, Oslo University Hospital, Oslo, Norway.
Author details
1Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2Department
of Dermatology, Oslo University Hospital, Oslo, Norway. 3Department of
Research, Education and Innovation, Oslo University Hospital, Oslo, Norway.
4Department of Microbiology, Oslo University Hospital, Oslo, Norway.
5Norwegian National Advisory Unit on Breastfeeding, Womens and Children´s
Division, Oslo University Hospital, Oslo, Norway.
Received: 14 February 2015 Accepted: 29 April 2015
References
1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI.
Global variations in prevalence of eczema symptoms in children from
ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–58 e1223.
2. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.
3. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions
of atopic dermatitis. British J Dermatol. 1974;90(5):525–30.
4. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.
Guidelines of care for the management of atopic dermatitis: section 2.
Management and treatment of atopic dermatitis with topical therapies.
J Am Acad Dermatol. 2014;71(1):116–32.
5. Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al.
Factors associated with steroid phobia in caregivers of children with atopic
dermatitis. Pediat Dermatol. 2013;30(1):29–35.
6. Ehrlich P. Über Immunität durch Vererbung und Säugung. Zeitschrift für
Hygiene und Infectionkrankheiten. 1892;12:183–203.
7. Hornell A, Lagstrom H, Lande B, Thorsdottir I. Breastfeeding, introduction
of other foods and effects on health: a systematic literature review for the
5th Nordic Nutrition Recommendations. Food Nutrition Res. 2013;57:20823.
Berents et al. BMC Dermatology  (2015) 15:7 Page 7 of 78. Hosea Blewett HJ, Cicalo MC, Holland CD, Field CJ. The immunological
components of human milk. Adv Food Nutr Res. 2008;54:45–80.
9. Farahani LA, Ghobadzadeh M, Yousefi P. Comparison of the Effect of
Human Milk and Topical Hydrocortisone 1% on Diaper Dermatitis.
Pediat Dermatol. 2013;30(6):725–9.
10. Baynham JT, Moorman MA, Donnellan C, Cevallos V, Keenan JD.
Antibacterial effect of human milk for common causes of paediatric
conjunctivitis. Br J Ophthalmol. 2013;97(3):377–9.
11. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm
Venereol (Stockholm). 1980;92:44–7.
12. European Task Force on Atopic Dermatitis. Severity scoring of atopic
dermatitis: the SCORAD index. Consensus Report of the European Task
Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
13. Sugama J, Matsui Y, Sanada H, Konya C, Okuwa M, Kitagawa A. A study of
the efficiency and convenience of an advanced portable wound
measurement system (VISITRAK). J Clin Nurs. 2007;16(7):1265–9.
14. Buescher ES. Anti-inflammatory characteristics of human milk: how, where,
why. Adv Exp Med Biol. 2001;501:207–22.
15. Murphey DK, Buescher ES. Human colostrum has anti-inflammatory activity
in a rat subcutaneous air pouch model of inflammation. Pediatr Res.
1993;34(2):208–12.
16. Grey KR, Davis EP, Sandman CA, Glynn LM. Human milk cortisol is
associated with infant temperament. Psychoneuroendocrinology.
2013;38(7):1178–85.
17. Lindemann PC, Foshaugen I, Lindemann R. Characteristics of breast milk
and serology of women donating breast milk to a milk bank. Arch Dis Child
Fetal Neonatal Ed. 2004;89(5):F440–1.
18. Brandtzaeg P. The mucosal immune system and its integration with the
mammary glands. J Pediatr. 2010;156(2 Suppl):S8–15.
19. Ibhanesebhor SE, Otobo ES. In vitro activity of human milk against the
causative organisms of ophthalmia neonatorum in Benin City. Nigeria J
Trop Pediatr. 1996;42(6):327–9.
20. Vural G, Kisa S. Umbilical cord care: a pilot study comparing topical human
milk, povidone-iodine, and dry care. J Obstet Gynecol Neonatal Nurs.
2006;35(1):123–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
